Costagliola D - Search Results

1

IL-2 therapy: potential impact of the CD4 cell count at initiation on clinical efficacy--results from the ANRS CO4 cohort.

Fontas E, Kousignian I, Pradier C, Poizot-Martin I, Durier C, Weiss L, Levy Y, Costagliola D; FHDH ANRS CO4; ANRS CO14. Fontas E, et al. Among authors: costagliola d. J Antimicrob Chemother. 2010 Oct;65(10):2215-23. doi: 10.1093/jac/dkq296. Epub 2010 Aug 11. J Antimicrob Chemother. 2010. PMID: 20702463

2

Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor.

Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M, Berlureau P, Dupont C, Fabbro-Peray P, Poizot-Martin I, Costagliola D. Grabar S, et al. Among authors: costagliola d. AIDS. 2000 Jan 28;14(2):141-9. doi: 10.1097/00002030-200001280-00009. AIDS. 2000. PMID: 10708284 Clinical Trial.

3

Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.

Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L. Grabar S, et al. Among authors: costagliola d. Ann Intern Med. 2000 Sep 19;133(6):401-10. doi: 10.7326/0003-4819-133-6-200009190-00007. Ann Intern Med. 2000. PMID: 10975957

4

Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082.

Katlama C, Carcelain G, Duvivier C, Chouquet C, Tubiana R, De Sa M, Zagury L, Calvez V, Autran B, Costagliola D; ILSTIM. Katlama C, et al. Among authors: costagliola d. AIDS. 2002 Oct 18;16(15):2027-34. doi: 10.1097/00002030-200210180-00007. AIDS. 2002. PMID: 12370501 Clinical Trial.

5

Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus.

del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, Gastaut JA, Costagliola D, Rosenthal E; French Hospital Database on HIV Clinical Epidemiologic Group. del Giudice P, et al. Among authors: costagliola d. J Infect Dis. 2002 Nov 1;186(9):1366-70. doi: 10.1086/344325. Epub 2002 Oct 11. J Infect Dis. 2002. PMID: 12402211

6

Markov modelling of changes in HIV-specific cytotoxic T-lymphocyte responses with time in untreated HIV-1 infected patients.

Kousignian I, Autran B, Chouquet C, Calvez V, Gomard E, Katlama C, Rivière Y, Costagliola D; IMMUNOCO Study Group. Kousignian I, et al. Among authors: costagliola d. Stat Med. 2003 May 30;22(10):1675-90. doi: 10.1002/sim.1404. Stat Med. 2003. PMID: 12720304

7

Bivariate longitudinal model for the analysis of the evolution of HIV RNA and CD4 cell count in HIV infection taking into account left censoring of HIV RNA measures.

Thiébaut R, Jacqmin-Gadda H, Leport C, Katlama C, Costagliola D, Le Moing V, Morlat P, Chêne G; APROCO Study Grooup. Thiébaut R, et al. Among authors: costagliola d. J Biopharm Stat. 2003 May;13(2):271-82. doi: 10.1081/BIP-120019271. J Biopharm Stat. 2003. PMID: 12729394

8

Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.

Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, Plaisance N, Tissot-Dupont H, Boue F, Lang JM, Costagliola D. Herida M, et al. Among authors: costagliola d. J Clin Oncol. 2003 Sep 15;21(18):3447-53. doi: 10.1200/JCO.2003.01.096. J Clin Oncol. 2003. PMID: 12972519

9

Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.

Kousignian I, Abgrall S, Duval X, Descamps D, Matheron S, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV. Kousignian I, et al. Among authors: costagliola d. J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):50-7. doi: 10.1097/00126334-200309010-00007. J Acquir Immune Defic Syndr. 2003. PMID: 14501793

10

Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.

Wirden M, Delaugerre C, Marcelin AG, Ktorza N, Ait Mohand H, Dominguez S, Schneider L, Ghosn J, Pauchard M, Costagliola D, Katlama C, Calvez V. Wirden M, et al. Among authors: costagliola d. Antimicrob Agents Chemother. 2004 Feb;48(2):644-7. doi: 10.1128/AAC.48.2.644-647.2004. Antimicrob Agents Chemother. 2004. PMID: 14742228 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

726 results

Search Page